COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA
The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
1 . A composition comprising:
(a) an isolated fully human monoclonal anti-M2e antibody composition, wherein the antibody comprises a V H CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72); a V H CDR2 region comprising the amino acid sequence of FIYYGGNTKYNPSLKS (SEQ ID NO: 74); a V H CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76); a V L CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59); a V L CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); and a V L CDR3 region comprising the amino acid sequence of QQSYSPPLT (SEQ ID NO: 63); and
(b) an oseltamivir composition.
2 . A composition comprising:
(a) an isolated fully human monoclonal anti-M2e antibody composition, wherein the antibody comprises a V H CDR1 region comprising the amino acid sequence of SNYMS (SEQ ID NO: 103); a V H CDR2 region comprising the amino acid sequence of VIYSGGSTYYADSVK (SEQ ID NO: 105); a V H CDR3 region comprising the amino acid sequence of CLSRMRGYGLDV (SEQ ID NO: 107); a V L CDR1 region comprising the amino acid sequence of RTSQSISSYLN (SEQ ID NO: 92); a V L CDR2 region comprising the amino acid sequence of AASSLQSGVPSRF (SEQ ID NO: 94); and a V L CDR3 region comprising the amino acid sequence of QQSYSMPA (SEQ ID NO: 96); and
(b) an oseltamivir composition.
3 . A pharmaceutical composition comprising the composition of claim 1 or 2 and a pharmaceutical carrier.
4 . The composition of any one of claims 1 - 3 , wherein said oseltamivir is oseltamivir phosphate.
5 . The composition of any one of claims 1 - 3 , further comprising a second anti-influenza A antibody.
6 . The composition of claim 5 , wherein said second anti-influenza A antibody is an anti-M2e antibody or an anti-HA antibody.
7 . A method for the treatment or prevention of an influenza virus infection in a subject, comprising administering to the subject the composition of any one of claims 1 - 3 .
8 . The method of claim 7 , wherein said anti-M2e antibody is administered at a dosage of between 10 and 40 mg/kg/day.
9 . The method of claim 8 , wherein said anti-M2e antibody is administered once or twice per day.
10 . The method of claim 7 , wherein said oseltamivir composition is administered at a dosage of 10 mg/kg.
11 . The method of claim 10 , wherein said oseltamivir composition is administered once or twice per day.
12 . The method of claim 7 , wherein said anti-M2e antibody or said oseltamivir composition is administered prior to influenza infection.
13 . The method of claim 7 , wherein said anti-M2e antibody or said oseltamivir composition is administered after influenza infection.
14 . The method of claim 13 , wherein said anti-M2e antibody is administered within 4 days or 48 hours after influenza infection.
15 . The method of claim 7 , wherein said anti-M2e antibody and said oseltamivir composition are administered simultaneously or sequentially.
16 . The method of claim 15 , wherein said anti-M2e antibody and said oseltamivir composition are administered sequentially, and wherein said anti-M2e antibody is administered before said oseltamivir composition.
17 . The method of claim 15 , wherein said anti-M2e antibody and said oseltamivir composition are administered sequentially, and wherein said anti-M2e antibody is administered after said oseltamivir composition.
18 . A kit comprising the composition of claim 3 .